KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Long-Term Debt Repayments (2016 - 2025)

Pfizer (PFE) has disclosed Long-Term Debt Repayments for 17 consecutive years, with $3.0 billion as the latest value for Q4 2025.

  • On a quarterly basis, Long-Term Debt Repayments changed N/A to $3.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $6.8 billion, a 200.31% increase, with the full-year FY2025 number at $6.8 billion, up 200.31% from a year prior.
  • Long-Term Debt Repayments was $3.0 billion for Q4 2025 at Pfizer, down from $3.8 billion in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $3.8 billion in Q2 2025 to a low of $269.0 million in Q2 2023.
  • A 5-year average of $1.6 billion and a median of $1.3 billion in 2023 define the central range for Long-Term Debt Repayments.
  • Peak YoY movement for Long-Term Debt Repayments: crashed 83.28% in 2023, then skyrocketed 364.68% in 2024.
  • Pfizer's Long-Term Debt Repayments stood at $1.0 billion in 2021, then soared by 60.74% to $1.6 billion in 2022, then dropped by 19.2% to $1.3 billion in 2023, then dropped by 23.08% to $1.0 billion in 2024, then soared by 200.7% to $3.0 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Long-Term Debt Repayments are $3.0 billion (Q4 2025), $3.8 billion (Q2 2025), and $1.0 billion (Q2 2024).